Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

NCT00824356 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinitis

Interventions

DRUG: GSK1004723 (200mg)
OTHER: Placebo
DRUG: GSK1004723 (1000mg)

Sponsor

GlaxoSmithKline